scholarly journals Immunomagnetic separation of circulating tumor cells with microfluidic chips and their clinical applications

2020 ◽  
Vol 14 (4) ◽  
pp. 041502
Author(s):  
Hongmei Chen ◽  
Yong Li ◽  
Zhifeng Zhang ◽  
Shuangshou Wang
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Immunomagnetic Separation ◽  
Clinical Applications ◽  
Microfluidic Chips

Clinical Applications of Circulating Tumor Cells in Breast Cancer

2019 ◽  
pp. 147-160 ◽  
Author(s):  
Erin F. Cobain ◽  
Costanza Paoletti ◽  
Jeffrey B. Smerage ◽  
Daniel F. Hayes
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Applications

scholarly journals Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities

2020 ◽  
Vol 10 (9) ◽  
pp. 3311
Author(s):  
Maggie Banys-Paluchowski ◽  
Florian Reinhardt ◽  
Tanja Fehm
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Therapy Monitoring ◽  
Metastatic Breast ◽  
Study Groups ◽  
Clinical Applications ◽  
Response To Treatment ◽  
Cellsearch System

Circulating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, detection of CTCs correlates with clinical outcome in early and metastatic settings. CTC persistence beyond first cycle of palliative chemotherapy indicates poor response to treatment in metastatic situation. Beyond prognostication and therapy monitoring, CTC counts can guide treatment decisions in hormone receptor positive HER2-negative metastatic breast cancer. Furthermore, CTC-based therapy interventions are currently under investigation in clinical trials. In this review, we focus on the current state of knowledge and possible clinical applications of CTC diagnostics in patients with metastatic breast cancer.

Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors

2013 ◽  
Vol 31 (3) ◽  
pp. 365-372 ◽  
Author(s):  
Mohid S. Khan ◽  
Amy Kirkwood ◽  
Theodora Tsigani ◽  
Jorge Garcia-Hernandez ◽  
John A. Hartley ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Neuroendocrine Tumors ◽  
Prognostic Markers ◽  
Prognostic Significance ◽  
Elevated Serum ◽  
Progression Free Survival ◽  
Tumor Grade ◽  
Immunomagnetic Separation ◽  
Tumor Burden

Purpose To determine the prognostic significance of circulating tumor cells (CTCs) in patients with neuroendocrine cancer. Patients and Methods In this single-center prospective study, 176 patients with measurable metastatic neuroendocrine tumors (NETs) were recruited. CTCs were measured using a semiautomated technique based on immunomagnetic separation of epithelial cell adhesion molecule–expressing cells. Results Overall, 49% patients had ≥ one CTC, 42% had ≥ two CTCs, and 30% had ≥ five CTCs in 7.5 mL blood. Presence of CTCs was associated with increased burden, increased tumor grade, and elevated serum chromogranin A (CgA). Using a 90-patient training set and 85-patient validation set, we defined a cutoff of < one or ≥ one as the optimal prognostic threshold with respect to progression-free survival (PFS). Applying this threshold, the presence of ≥ one CTC was associated with worse PFS and overall survival (OS; hazard ratios [HRs], 6.6 and 8.0, respectively; both P < .001). In multivariate analysis, CTCs remained significant when other prognostic markers, grade, tumor burden, and CgA were included. Within grades, presence of CTCs was able to define a poor prognostic subgroup. For grade 1, HRs were 5.0 for PFS (P = .017) and 7.2 for OS (P = .023); for grade 2, HRs were 3.5 for PFS (P = .018) and 5.2 for OS (P = .036). Conclusion CTCs are a promising prognostic marker for patients with NETs and should be assessed in the context of clinical trials with defined tumor subtypes and therapy.

Plasma functionalized PDMS microfluidic chips: towards point-of-care capture of circulating tumor cells

2011 ◽  
Vol 21 (24) ◽  
pp. 8841 ◽  
Author(s):  
Mahaveer D. Kurkuri ◽  
Fares Al-Ejeh ◽  
Jun Yan Shi ◽  
Dennis Palms ◽  
Clive Prestidge ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Point Of Care ◽  
Microfluidic Chips
Sign in / Sign up

Export Citation Format

Share Document